LONDON - A non-surgical treatment for low-risk prostate cancer in which doctors inject a light-sensitive drug derived from deep-sea bacteria into a patient's bloodstream was shown in a trial to kill cancer cells without destroying healthy tissue. "These results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate," said Mark Emberton, a University College London consultant urologist who led the trial. The treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.